Rare Disease Therapeutics, Inc.
Rare Disease Therapeutics, Inc. (RDT) is America’s first exclusively orphan drug company committed to developing and marketing drugs for rare disorders. RDT is dedicated to patients with unmet medical needs including envenomations. RDT and Laboratorios Silanes, S.A. de C.V. have a joint development and distribution agreement for F(ab’)₂ antivenoms. Silanes, founded in 1943, is a world leader in the development and marketing of antivenom for snake, scorpion, and spider envenomation on three continents.
Brands: ANAVIP® [crotalidae immune F(ab′)₂ (equine)] , ANASCORP® [centruroides (scorpion) immune F(ab′)₂ (equine)] injection